Showing results (1301-1310 of 3,352) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|May 19, 2006
Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trialLaura Bojke, Mark Sculpher, Richard Stephens, et al.Pharmacoeconomics|June 10, 2006
Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysisGeorge Dranitsaris, Mark Vincent, Mark CrowtherPharmacoeconomics|June 20, 2008
Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in EuropeBjörn Wettermark, Brian Godman, Karolina Andersson, et al.Pharmacoeconomics|June 20, 2008
Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UKRay Gani, Gavin Giovannoni, David Bates, et al.Pharmacoeconomics|October 28, 2006
Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?Andrew H Briggs, Adrian R LevyPharmacoeconomics|October 28, 2006
Economic evaluations in the canadian common drug reviewAndreas LaupacisPharmacoeconomics|February 21, 2004
A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspectiveManishi Prasad, Peter Wahlqvist, Rich Shikiar, et al.Pharmacoeconomics|September 15, 2004
Pharmacoeconomic implications of new therapies in sepsisKelly A Wood, Derek C AngusPharmacoeconomics|June 24, 2004
A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancerJeremy Holmes, David Dunlop, Lindsay Hemmett, et al.Pharmacoeconomics|June 24, 2004
A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgerySean D Sullivan, Bruce L Davidson, Susan R Kahn, et al.Pageof 336